Compare TPH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPH | NUVB |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | TPH | NUVB |
|---|---|---|
| Price | $35.34 | $8.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $41.40 | $10.56 |
| AVG Volume (30 Days) | 866.1K | ★ 5.5M |
| Earning Date | 02-17-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.42 | N/A |
| Revenue | ★ $3,751,941,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $609.55 |
| Revenue Next Year | N/A | $197.91 |
| P/E Ratio | $9.53 | ★ N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $27.90 | $1.54 |
| 52 Week High | $38.96 | $9.75 |
| Indicator | TPH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 46.68 |
| Support Level | $30.51 | $8.04 |
| Resistance Level | $32.26 | $9.10 |
| Average True Range (ATR) | 0.88 | 0.45 |
| MACD | 0.20 | -0.21 |
| Stochastic Oscillator | 95.97 | 5.52 |
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. The company's financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.